Amyris (NASDAQ:AMRS) Given a $11.00 Price Target at HC Wainwright

HC Wainwright set a $11.00 target price on Amyris (NASDAQ:AMRS) in a report published on Tuesday, February 5th. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other equities analysts have also recently weighed in on the stock. Zacks Investment Research upgraded shares of Amyris from a strong sell rating to a hold rating in a research report on Tuesday, January 15th. BidaskClub lowered shares of Amyris from a hold rating to a sell rating in a research report on Tuesday, November 13th. Finally, B. Riley lowered their target price on shares of Amyris from $10.00 to $8.00 and set a buy rating on the stock in a research report on Wednesday, November 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $8.83.

Shares of Amyris stock traded down $0.09 on Tuesday, reaching $4.65. The stock had a trading volume of 908,382 shares, compared to its average volume of 5,735,396. The company has a market cap of $377.27 million, a P/E ratio of -1.52 and a beta of 0.29. Amyris has a 1 year low of $2.64 and a 1 year high of $9.28.

In other news, COO Eduardo Alvarez purchased 11,834 shares of the business’s stock in a transaction dated Thursday, December 13th. The stock was bought at an average cost of $4.23 per share, with a total value of $50,057.82. Following the purchase, the chief operating officer now directly owns 333,876 shares of the company’s stock, valued at $1,412,295.48. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 21.80% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. Wells Fargo & Company MN grew its position in Amyris by 50.6% during the third quarter. Wells Fargo & Company MN now owns 41,903 shares of the biotechnology company’s stock worth $333,000 after buying an additional 14,075 shares in the last quarter. Schwab Charles Investment Management Inc. acquired a new stake in Amyris during the second quarter worth approximately $292,000. Caption Management LLC acquired a new stake in Amyris during the fourth quarter worth approximately $50,000. Gilder Gagnon Howe & Co. LLC acquired a new stake in Amyris during the third quarter worth approximately $7,828,000. Finally, JPMorgan Chase & Co. grew its position in Amyris by 96.2% during the third quarter. JPMorgan Chase & Co. now owns 446,909 shares of the biotechnology company’s stock worth $3,548,000 after buying an additional 219,081 shares in the last quarter. 32.07% of the stock is owned by hedge funds and other institutional investors.

About Amyris

Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.

Recommended Story: What is Cost of Debt?

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.